Omega-Point — Scientific Reasoning Engine

The Status Quo

The LLM knows every experiment ever run.
That’s not what frontier science needs.

When you ask an LLM about reversing aging, it returns a sophisticated summary of what’s already published. Retrieval at scale. The most important experiments — the ones nobody has run yet — are invisible to it by definition.

The Retrieval Trap

Only knows what’s published

LLMs are trained on existing literature. Ask about the frontier and they return sophisticated summaries of the known — senolytics, rapamycin, OSK. All published. All already being tried. None of it tells you what to do next.

The Complexity Barrier

Too large for any individual

“Achieve biological immortality” spans 50+ research domains, thousands of papers, millions of possible experimental designs. No individual scientist — no matter how brilliant — can hold the full problem space and identify where the real gaps are.

The Hypothesis Vacuum

Experiments chosen by intuition

Without a rigorous map of what’s unknown versus what’s needed, even expert researchers design from intuition. The result: descriptive experiments that teach us little when they succeed, and nothing when they fail.

What if every experiment moved you forward whether it confirmed or refuted the hypothesis — because it was designed to discriminate between competing explanations of something genuinely unknown?

The Core Insight

Map what your goal requires.
Map what science knows.
Design for the gap.

Omega-Point gives AI a structured job: for each gap between what your goal requires and what science has answered, generate competing hypotheses and design experiments that discriminate between them.

01

Decompose the goal into Requirement Atoms Each RA is solution-neutral and binds exactly one state variable, perturbation class, timescale, and failure shape. No genes, no drugs — only what the system must do to succeed.

02

Map what science actually knows Scientific Pillars across MECE research domains — including non-obvious adjacent fields (condensed matter physics, information theory, control systems) that most biologists overlook.

03

Find the epistemic gaps Where requirements have no scientific answer. These become Frontier Questions — unanswerable by literature search. If a question could be answered by reading a paper, it’s rejected.

04

Design experiments that close them Competing hypotheses, discriminator questions, fully-specified S·I·M·T protocols: exact cell line, catalog numbers, doses, assay, statistical power threshold.

goal achieve biological immortality

01 What goal requires

02 What science knows

Cellular waste clearance

✓

Autophagy · LC3-II flux

Autophagy flux is well-characterized via LC3-II lipidation and p62 degradation assays. Multiple pharmacological handles exist (rapamycin, spermidine).

Circadian synchrony

✓

Clock-gene oscillation

Core BMAL1/CLOCK/PER oscillation is well-mapped. Circadian disruption accelerates aging phenotypes in model organisms.

ECM mechanical homeostasis

?

Stiffening known; bistability?

ECM stiffening with age is documented, but whether tissue matrix states form a true bistable attractor — with a tipping point — is untested. No reversibility pathway has been demonstrated.

Inter-tissue phase coherence

?

No Kuramoto model yet

Whether multiple tissue clocks synchronize via Kuramoto coupling has never been formalized. Therapeutic manipulation of cross-tissue coherence is unexplored.

Epigenome full reversibility

?

Bistability uncharted

Yamanaka factor reprogramming shows partial epigenetic reversion, but full bistability — a stable young attractor state — is theoretical. No transition model exists.

03

Epistemic Frontier

043 gaps → new experiments

Frontier Questions › Hypotheses › Experiments

9 Reasoning Agents

Four phases.
One coherent reasoning chain.

Each agent has a single, constrained job. The output of each step becomes the context for the next — building a chain of reasoning that forces the LLM to operate only at the frontier. Click any agent to see what it does.

Q₀

Master
Question

G

Goal
Pillars

RA

Requirement
Atoms

D

Research
Domains

SP

Scientific
Pillars

GAP

L3

Frontier
Questions

IH

Competing
Hypotheses

L4

Tactical
Questions

L6

Experiments
S·I·M·T

I Decompose the Goal steps 1 – 3

01

The Initiator

Transforms vague goal → dense, solution-neutral master question Q₀

Q₀

02

The Immortalist Architect

Inverse Failure Analysis → 3–6 MECE Goal Pillars + Bridge Lexicon

G

03

The Requirements Engineer

Each Pillar → 5–9 atomic testable Requirements; no genes, no drugs

RA

II Map Scientific Reality steps 4 – 5

04

The Domain Mapper

8–12 MECE research domains; deliberately includes non-obvious adjacent fields

D

05

The Domain Specialist

15–25 evidence-based Scientific Pillars per domain (PubMed, Semantic Scholar, OpenAlex)

SP

III Find the Epistemic Gap step 6 · the core innovation

06

The Strategic Science Officer

Compares Requirements vs Science. Questions that could be answered by reading a paper are rejected. Only genuine frontier questions — unanswerable without a new experiment — survive.

L3

IV Design Discriminating Experiments steps 7 – 9

07

The Instantiation Gatekeeper

Each L3 → 4–7 competing Hypotheses; must include ≥1 heretical + ≥1 cross-domain transfer

IH

08

The Lead Investigative Officer

L3 + IHs → Tactical Questions; ≥50% must be discriminator questions that pit IHs against each other

L4

09

The Lead Tactical Engineer

Each L4 → L6 leaf: System · Intervention · Meter · Threshold — with catalog numbers, doses, and statistical power targets

L6

V Select the Best Experiments step 10 · final gate

10

The Strategic Ranker

Scores every L6 experiment against six criteria. Enforces mechanistic diversity — no two selected experiments share both mechanism and assay. Surfaces the top-ranked portfolio.

★

1

Discriminating power — qualitatively different results under each competing hypothesis

2

Causal attribution — controlled intervention, unambiguous cause-effect

3

Gap size — delta between field assumptions and what this experiment first establishes

4

Any-outcome interpretability — positive, negative, and null results all resolve to clear conclusions

5

Speed to result — interpretable data within a 3-year ceiling

6

Protocol verifiability — primary readout, controls, and threshold independently replicable

Experiments without a competing hypothesis to discriminate, or where the null result is uninterpretable, are excluded regardless of other scores.

Every L6 experiment is inconceivable without its full chain Q₀ → RA → SP → L3 → IH → L4 → L6. If it could have been conceived from a literature review, it is rejected. Phase V then scores and ranks all generated experiments — only the top portfolio survives.

From “achieve biological immortality”

Not “experiments to try.”
Experiments to run tomorrow.

A single run produces hundreds of fully-specified L6 experiments. The pipeline's final step scores every one by the six criteria above and surfaces the top-ranked portfolio. Below: the complete reasoning chain for the #1-ranked experiment from one real run.

Full reasoning chain — one path through the graph Rank #1 of hundreds · Score 92/100

Q₀

Master Question

In adult Homo sapiens 60–80 yo, what strategy can restore whole-organism biological age to 25–30 yo and sustain it for 50–150 years?

G4

Goal Pillar

Structural & matrix integrity — ECM mechanical homeostasis must be maintained without continuous intervention.

RA

Requirement Atom

ECM stiffness must remain below the aged range (≤4 kPa) under ordinary physiological loading for 50+ years without continuous therapy.

SP

Scientific Pillar

Kramers rate theory applied to chromatin: BMAL1 active/silenced states behave as thermodynamically bistable wells. ECM stiffening increases transition rates — but whether a bifurcation exists is unknown.

L3

Frontier Question

Does ECM stiffness crossing ~8 kPa trigger a discontinuous epigenetic clock entropy jump — a bifurcation point — in aged fibroblasts? (Unanswerable by literature search.)

L4

Tactical Question

Across a stiffness titration (0.2–40 kPa), at what ECM Young's modulus does epigenetic clock entropy show a discontinuous bifurcation?

L6

Experiment

The fully-specified protocol below. Inconceivable without every level above.

S · I · M · T Specification — complete protocol

Score 92 Genius 9/10 Feasibility 8/10

S

System

IMR-90 human lung fibroblasts (ATCC CCL-186), passage 30–32. Genipin crosslinker (Sigma G4401) titrated 0.05–2 mg/mL in type-I collagen gels (Corning 354249) to span 0.2–40 kPa Young's modulus. n=6 biological replicates per stiffness condition.

I

Intervention

8-step stiffness titration: 0.2, 0.8, 2, 4, 6, 8, 20, 40 kPa Young's modulus. 5-day incubation. Stiffness verified by AFM nanoindentation. Internal control: parallel soft-gel (0.2 kPa) + rigid plastic (≫40 kPa).

M

Meter

Whole-genome DNAm profiling (Illumina EPIC array, Cat# 20044471). Horvath 2013 clock and GrimAge clock applied per sample. Entropy = H = −Σpᵢlog₂(pᵢ) per CpG island block. Bifurcation: nonlinear fit (R² >0.90 inflection).

T

Threshold

Discontinuous entropy jump ≥2× background noise at a single stiffness transition point, p<0.01 permutation test. Bayesian changepoint analysis (PELT algorithm). ~9 months to first result. Cost ≈ $48 k.

RANK 1 Score 92/100 Genius 9/10 Feasibility 8/10 ~9 months to result

Does collagen gel stiffness crossing ~8 kPa trigger a discontinuous epigenetic clock entropy jump in aged fibroblasts?

Why this is novel: First systematic ECM stiffness titration against whole-genome epigenetic clock. The Kramers bistability framing — imported from condensed matter physics — predicts a discontinuous phase transition in epigenetic age at a specific mechanical threshold. This connection has never been tested.

S · I · M · T Specification complete protocol

S

System

IMR-90 human lung fibroblasts (ATCC CCL-186), passage 30, representing replicatively aged cells with measurable epigenetic clock advancement. Cultured on 8-step methacrylated collagen hydrogel gradient: 0.2, 0.6, 1.5, 3, 8, 15, 25, 40 kPa, validated by AFM nanoindentation.

I

Intervention

Methacrylated collagen (Advanced BioMatrix Cat# 5153) photocrosslinked with Irgacure 2959 (Sigma Cat# 410896). Genipin crosslinker titration (0–2 mM) to achieve calibrated stiffness steps. Each condition: 14 days culture before endpoint analysis.

M

Meter

Illumina Infinium MethylationEPIC v2.0 BeadChip (Cat# 20044471) on gDNA extracted with Qiagen AllPrep (Cat# 80204). DNAm biological age computed via Horvath 2013 multi-tissue clock and GrimAge. Clock entropy per sample.

T

Threshold

Discontinuous clock entropy jump ≥3 years DNAm age shift between adjacent stiffness steps, p<0.01 by Davies breakpoint test. Positive result establishes ECM mechanical bistability as epigenetic attractor.

RANK 2 Score 91/100 Genius 7.5/10 Feasibility 9/10 ~7 months to result

Does the macrophage inflammatory attractor exhibit irreversible hysteresis — asymmetric LPS-forward / IL-4-reverse dose titration curves in same-donor aged and young primary human macrophages?

Why this is novel: First direct empirical test of bistable hysteresis in aged human macrophages. Applies Kramers stochastic-escape framework from thermodynamics to macrophage phenotype transitions. If hysteresis width >1 log₁₀ unit in aged donors, the inflammaging attractor is energy-barrier limited — requiring fundamentally different therapy (combination, not incremental dosing).

S · I · M · T Specification complete protocol

S

System

Primary human PBMC-derived macrophages from 10 donors aged 63–79 years and 10 donors aged 24–33 years (sex-matched pairs, 5M/5F per age group). Boston Children's Hospital Biobank IRB. 7-day M-CSF maturation before assay.

I

Intervention

FORWARD: LPS (Sigma-Aldrich L4391) at 11 concentrations (0.001–1000 ng/mL) from M0 baseline, 24h. REVERSE: IL-4 (PeproTech 214-14) 11 concentrations (0.01–300 ng/mL) from M1 state, 24h. Same-donor paired design.

M

Meter

Flow cytometry (BD FACSCanto II) at 24h: CD86 PE-Cy7 (BD 563833, 1:100), CD163 PE (BioLegend 333606, 1:100), CD206 APC (BioLegend 321110, 1:100), HLA-DR BV421 (BD 562806, 1:50). EC50 extracted by 4PL fit.

T

Threshold

Hysteresis width (HW) = |log₁₀(EC50_forward) − log₁₀(EC50_reverse)| > 1.0 log₁₀ unit, R²≥0.90. Aged HW significantly greater than young HW (p<0.05 paired t-test). Confirms catastrophe model.

RANK 4 Score 89/100 Genius 9/10 Feasibility 8/10 ~4 months to result

Does 14-day PF-670462 treatment reduce inter-tissue circadian frequency dispersion (σ) and restore phase coherence index in aged Per2::Luc mice — validating the Kuramoto coupling threshold as the therapeutic target?

Why this is novel: First in vivo test of the Kuramoto coupling threshold model in aging. Applies mathematical physics of coupled oscillators (synchronization theory) to inter-tissue circadian aging — a completely novel framing. If σ reduction crosses the K>πσ/2 threshold, the system locks into synchrony, establishing a quantitative design principle for all future circadian aging interventions.

S · I · M · T Specification complete protocol

S

System

22–24 month C57BL/6J Per2::Luciferase knock-in mice (JAX #006852). Four arms n=12: (1) aged vehicle, (2) aged PF-670462 low (3 mg/kg), (3) aged PF-670462 high (20 mg/kg), (4) young (4–6mo) vehicle control. Multi-tissue ex vivo bioluminescence: EDL muscle, adipose, spleen, dermis, nasal turbinate.

I

Intervention

PF-670462 (MedChemExpress HY-12459, purity ≥99%) or vehicle (10% DMSO/0.9% saline) i.p. at ZT2 daily for 14 days. On day 15: tissues harvested at ZT6, sliced to 250 µm, placed in LumiCycle recording medium with luciferin.

M

Meter

LumiCycle 32 bioluminescence for 7 days. Period extracted per tissue via BioDare2. σ = SD of 5 tissue periods per animal. Phase Coherence Index (PCI) = |Σe^iφⱼ|/N across tissues at day 3 of recording.

T

Threshold

σ reduction ≥30% vs aged vehicle AND PCI increase ≥0.2 absolute vs aged vehicle, both p<0.05. Dose-response confirms σ-reduction as the critical variable. n=12/arm, 6-week total runtime.

One sentence. Total coverage.

The first system that can hold the entire problem space of a grand scientific question.

“Achieve biological immortality” is a problem space no individual scientist — and no single LLM prompt — can fully navigate. Omega-Point systematically covers every domain, every gap, every hypothesis branch. What takes a research team years to partially map takes Omega-Point ten minutes.

Q₀

1 master question

G

4–6 goal pillars

RA

20–45 requirement atoms

SP

400–600 scientific pillars surveyed

L3

30–60 frontier questions

IH

150–300 competing hypotheses

L6

500+ fully-specified experiments

500+

experiments generated

from one sentence of ambition

9

reasoning agents

each with a single constrained job

~10

minutes end-to-end

from prompt to ranked protocol list

6

reasoning levels deep

every experiment traceable to the goal

“Ambitious, non-trivial, extraordinary — yet realistic and executable. Experiments so ingenious nobody has done them before, yet so well-grounded they could run in a real lab tomorrow.”

— Omega-Point design principle

Early Access Program

For anyone who has ever asked
a question too big to answer alone.

Whether you're a researcher, a longevity enthusiast, a philosopher of science, or simply obsessed with a fundamental question — if you can state your goal in one sentence, Omega-Point will map the experimental frontier. Currently in closed beta.

Researchers & labs tackling fundamental biology, longevity, and neuroscience

Longevity advocates & enthusiasts mapping what's unknown in aging science

Philosophers & strategists reasoning about science as a system

Funders & investors looking for the highest-leverage open experiments

LLMs know everything science has discovered. Omega-Point reasons about what hasn’t been.

The LLM knows every experiment ever run.
That’s not what frontier science needs.

Only knows what’s published

Too large for any individual

Experiments chosen by intuition

Map what your goal requires.
Map what science knows.
Design for the gap.

Four phases.
One coherent reasoning chain.

Not “experiments to try.”
Experiments to run tomorrow.

Does collagen gel stiffness crossing ~8 kPa trigger a discontinuous epigenetic clock entropy jump in aged fibroblasts?

Does the macrophage inflammatory attractor exhibit irreversible hysteresis — asymmetric LPS-forward / IL-4-reverse dose titration curves in same-donor aged and young primary human macrophages?

Does 14-day PF-670462 treatment reduce inter-tissue circadian frequency dispersion (σ) and restore phase coherence index in aged Per2::Luc mice — validating the Kuramoto coupling threshold as the therapeutic target?

The first system that can hold the entire problem space of a grand scientific question.

For anyone who has ever asked
a question too big to answer alone.

Request received.

LLMs know everything science has discovered. Omega-Point reasons about what hasn’t been.

The LLM knows every experiment ever run. That’s not what frontier science needs.

Only knows what’s published

Too large for any individual

Experiments chosen by intuition

Map what your goal requires. Map what science knows. Design for the gap.

Four phases. One coherent reasoning chain.

Not “experiments to try.” Experiments to run tomorrow.

The first system that can hold the entire problem space of a grand scientific question.

For anyone who has ever asked a question too big to answer alone.

Request received.

The LLM knows every experiment ever run.
That’s not what frontier science needs.

Map what your goal requires.
Map what science knows.
Design for the gap.

Four phases.
One coherent reasoning chain.

Not “experiments to try.”
Experiments to run tomorrow.

For anyone who has ever asked
a question too big to answer alone.